Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.59 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.59 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.59 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11226180 | 0.98 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Nitric Acid SCHEMBL4070418 | 0.89 | TSHR (0.50) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Trifluoroacetic Acid SCHEMBL30725604 | 0.88 | KLK1 (0.51) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL9303333 | 0.88 | F2 (0.61) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL24891830 | 0.85 | KMT2A (0.64) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7913893 | 0.85 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7922546 | 0.85 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL211005 | 0.85 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL11316711 | 0.85 | PARP10 (0.61) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL22127093 | 0.83 | F2 (0.55) | F2PRSS1PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102731414-B | Method for preparing 4-[(4-chloro-2-pyrimidinyl) amino] cyanophenyl | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LTD | 2014-11-26 | — | — | CN | claimed |
| CN-102731414-A | Method for preparing 4-[(4-chloro-2-pyrimidinyl) amino] cyanophenyl | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LTD | 2012-10-17 | — | — | CN | claimed |
| CN-102718720-A | Method for preparing 4-[(4,6-dichloro-2-pyrimidyl) amino] cyanophenyl | NINGBO CHEMGOO PHARMA TECH CO LTD | 2012-10-10 | — | — | CN | claimed |
| US-20060148901-A1 | Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2006-07-06 | — | — | US | claimed |
| CN-1168707-C | 4-guanidinobenzamides antifertility compounds | 中国人民解放军第二军医大学 | 2004-09-29 | — | — | CN | claimed |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | ALLEN DARIN ARTHUR (US) | 2003-12-18 | — | — | US | claimed |
| CN-1401634-A | 4-guanidinobenzamides antifertility compounds | NO 2 MILITARY MEDICINE UNIV PL (CN) | 2003-03-12 | — | — | CN | claimed |
| EP-1242366-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | claimed |
| EP-0821689-B1 | TUMOR PROTEASE ACTIVATED PRODRUGS OF PHOSPHORAMIDE MUSTARD ANALOGS | DRUG INNOVATION & DESIGN INC (US) | 2001-07-04 | — | — | EP | claimed |
| WO-2001044172-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| EP-0821689-A1 | TUMOR PROTEASE ACTIVATED PRODRUGS OF PHOSPHORAMIDE MUSTARD ANALOGS | Drug Innovation & Design, Inc. (US) | 1998-02-04 | — | — | EP | claimed |
| US-5659061-A | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities | DRUG INNOVATION & DESIGN, INC. (US) | 1997-08-19 | — | — | US | claimed |
| WO-1996033198-A1 | TUMOR PROTEASE ACTIVATED PRODRUGS OF PHOSPHORAMIDE MUSTARD ANALOGS | DRUG INNOVATION & DESIGN, INC. (US) | 1996-10-24 | — | — | WO | claimed |
| CN-102718720-B | Method for preparing 4-[(4,6-dichloro-2-pyrimidyl) amino] cyanophenyl | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-102731414-B | Method for preparing 4-[(4-chloro-2-pyrimidinyl) amino] cyanophenyl | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LTD | 2014-11-26 | — | — | CN | disclosed |
| CN-102731414-A | Method for preparing 4-[(4-chloro-2-pyrimidinyl) amino] cyanophenyl | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LTD | 2012-10-17 | — | — | CN | disclosed |
| US-5659061-A | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities | DRUG INNOVATION & DESIGN, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1996033198-A1 | TUMOR PROTEASE ACTIVATED PRODRUGS OF PHOSPHORAMIDE MUSTARD ANALOGS | DRUG INNOVATION & DESIGN, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996033198-A1 | TUMOR PROTEASE ACTIVATED PRODRUGS OF PHOSPHORAMIDE MUSTARD ANALOGS | DRUG INNOVATION & DESIGN, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148901-A1 | Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein | F12, F11, F2 | F2 3/4885PRSS1 128/4885PRSS2 254/4885 |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | TFPI, HABP2, PLAT | F2 8/4885PRSS1 11/4885PRSS2 29/4885 |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | TFPI, SERPINE1, HABP2 | F2 8/4885PRSS1 7/4885PRSS2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.